Using olive pomace oil to reduce inflammation in Alzheimer's patients
Attenuation of Postprandial Inflammatory Processes in Alzheimer's Disease Patients by Consumption of Pomace Oil
This study is testing if olive pomace oil can help reduce inflammation in people with early-stage Alzheimer's disease compared to a different type of oil.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Spanish National Research Council Government |
| Locations | 1 site (Seville) |
| Trial ID | NCT06245616 on ClinicalTrials.gov |
What this trial studies
This research project investigates the effects of olive pomace oil on postprandial inflammation in patients with early-stage Alzheimer's disease. The study will recruit 40 adult volunteers diagnosed with mild Alzheimer's and 40 healthy individuals, dividing them into groups based on blood triglyceride levels. Participants will consume either olive pomace oil or high-oleic sunflower oil to assess the impact on inflammatory processes. The goal is to determine if bioactive compounds in olive pomace oil can mitigate inflammation linked to neurodegenerative diseases.
Who should consider this trial
Good fit: Ideal candidates are adults diagnosed with early-stage Alzheimer's disease who can consume breakfast independently.
Not a fit: Patients with significant psychiatric disorders, recent cardiovascular disease, or uncontrolled hypertension may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a dietary intervention to help reduce inflammation and potentially slow the progression of Alzheimer's disease.
How similar studies have performed: Previous studies have suggested that dietary components can influence inflammation in neurodegenerative diseases, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical diagnosis of Alzheimer's disease. * Adequate visual and hearing abilities. * Able to consume breakfast without help. Exclusion Criteria: * Clinically significant psychiatric disorders. * Systemic disease or infection that could affect safety. * Cardiovascular disease within the last 2 years. * Uncontrolled hypertension within the last 6 months. * Cancer within the last 5 years. * Drug or alcohol abuse within the last 2 years. * Insulin-dependent diabetes.
Where this trial is running
Seville
- Hospital Virgen de Valme — Seville, Spain (Recruiting)
Study contacts
- Study coordinator: Javier S Perona, PhD
- Email: perona@ig.csic.es
- Phone: +34 954611550
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.